Non Interventional Study Evaluating Efficacy and Safety in a Cohort of Elderly Patients of First Line Therapy With Avastin ® Regimen for Metastatic Colorectal Cancer

{
"level_sex_clusion_I": [
{
"value": "Male",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D008297"
}
},
{
"value": "Female",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D005260"
}
}
],
"level_age_clusion_I": [
{
"value": "Aged (65 to 79 years)",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D000368"
}
},
{
"value": "Aged, 80 and over (80 years and more)",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D000369"
}
}
],
"level_type_clusion_I": [
"Patients population"
],
"level_type_clusion_other": "",
"clusion_I": "Inclusion criteria: - Adult patient aged >= 75 years, - With metastatic adenocarcinoma of the colon or rectum, - For whom it has been decided to initiate first line treatment with Avastin®, concomitant to or no more than 2 months after the start of first line chemotherapy - Having received oral and written information about the study objectives and methods and having raised no objections to computer processing of the data in the medical record (indirectly named data). ",
"clusion_E": "Patient previously treated with Avastin®. - Patient already participating in a clinical trial evaluating a cytotoxic anticancer therapy and\/or an investigational new drug."
}